Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease

被引:46
|
作者
Kehagia, Angie A. [1 ,2 ]
Cools, Roshan [1 ,4 ]
Barker, Roger A. [3 ]
Robbins, Trevor W. [1 ,2 ]
机构
[1] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England
[2] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England
[3] Univ Cambridge, Dept Clin Neurosci, Cambridge Ctr Brain Repair, Cambridge CB2 3EB, England
[4] Radboud Univ Nijmegen, Med Ctr, Ctr Cognit Neuroimaging, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands
基金
英国惠康基金;
关键词
Parkinson's disease; Task switching; Dopamine; FRONTAL-LOBE DYSFUNCTION; SPATIAL WORKING-MEMORY; DATA-DRIVEN APPROACH; PREFRONTAL CORTEX; COGNITIVE CONTROL; BASAL GANGLIA; CLINICAL-IMPLICATIONS; ATTENTIONAL CONTROL; SET; DEFICITS;
D O I
10.1016/j.neuropsychologia.2009.01.002
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
This study sought to disambiguate the impact of Parkinson's disease (PD) on cognitive control as indexed by task set switching, by addressing discrepancies in the literature pertaining to disease severity and paradigm heterogeneity. A task set is governed by a rule that determines how relevant stimuli (stimulus set) map onto specific responses (response set). Task set switching may entail reconfiguration in either or both of these components. Although previous studies have shown that PD patients are impaired at switching between stimuli, in the present study not all patients were impaired at switching entire task sets, that is, both stimulus and response sets: compared with controls, patients with unilateral signs (Hoehn & Yahr Stage I) demonstrated intact switching, even following withdrawal from dopaminergic medication, while bilaterally affected Stage II patients were impaired. The parametric measure of Unified Parkinson's Disease Rating Scale (UPDRS)score predicted increasing switch costs within the patient group. These findings suggest that switching entire task sets may be a function of extrastriatal, possibly nondopaminergic pathology which increases as the disease progresses. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1117 / 1127
页数:11
相关论文
共 50 条
  • [1] Quantitative EEG reflects non-dopaminergic disease severity in Parkinson's disease
    Geraedts, Victor J.
    Marinus, Johan
    Gouw, Alida A.
    Mosch, Arne
    Stam, Cornelis J.
    van Hilten, Jacobus J.
    Contarino, Maria Fiorella
    Tannemaat, Martijn R.
    CLINICAL NEUROPHYSIOLOGY, 2018, 129 (08) : 1748 - 1755
  • [2] Parkinson's disease severity and use of dopaminergic medications
    Fang, John Y.
    Perez, Adriana
    Christine, Chadwick W.
    Leehey, Maureen
    Aminoff, Michael J.
    Boyd, James T.
    Morgan, John C.
    Dhall, Rohit
    Nicholas, Anthony P.
    Bodis-Wollner, Ivan
    Zweig, Richard M.
    Goudreau, John L.
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (03) : 297 - 299
  • [3] Increased conceptual switching by dopaminergic treatment in patients with Parkinson's disease
    Tiedt, Hannes O.
    Ehlen, Felicitas
    Klostermann, Fabian
    BRAIN AND COGNITION, 2020, 144
  • [4] Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect
    Jarvela, Juha T.
    Rinne, Juha O.
    Eskola, Olli
    Kaasinen, Valtteri
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (08) : 894 - 897
  • [5] Dopaminergic Agents and Nutritional Status in Parkinson's Disease
    Laudisio, Alice
    Vetrano, Davide L.
    Meloni, Eleonora
    Ricciardi, Diego
    Franceschi, Francesco
    Bentivoglio, Anna Rita
    Bernabei, Roberto
    Zuccala, Giuseppe
    MOVEMENT DISORDERS, 2014, 29 (12) : 1543 - 1547
  • [6] Understanding the dopaminergic deficits in Parkinson's disease: Insights into disease heterogeneity
    Lewis, Simon J. G.
    Barker, Roger A.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2009, 16 (05) : 620 - 625
  • [7] Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease
    Wylie, Scott A.
    van Wouwe, Nelleke C.
    Godfrey, Steven G.
    Bissett, Patrick G.
    Logan, Gordon D.
    Kanoff, Kristen E.
    Claassen, Daniel O.
    Neimat, Joseph S.
    van den Wildenberg, Wery P. M.
    NEUROPSYCHOLOGIA, 2018, 109 : 262 - 269
  • [8] Dopaminergic Medication Counteracts Conflict Adaptation in Patients With Parkinson's Disease
    Duthoo, Wout
    Braem, Senne
    Houtman, Femke
    Schouppe, Nathalie
    Santens, Patrick
    Notebaert, Wim
    NEUROPSYCHOLOGY, 2013, 27 (05) : 556 - 561
  • [9] Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson's Disease
    Sampedro, Frederic
    Martinez-Horta, Saul
    Marin-Lahoz, Juan
    Pagonabarraga, Javier
    Kulisevsky, Jaime
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (05) : 1567 - 1574
  • [10] Dopaminergic modulation of emotional memory in Parkinson’s disease
    Thomas D. Hälbig
    Ute A. Kopp
    Franziska Wodarz
    Joan C. Borod
    Jean-Michel Gracies
    Georg Ebersbach
    Andreas Kupsch
    Journal of Neural Transmission, 2008, 115 : 1159 - 1163